Document is current
Any future updates will be listed below
-
Authors
Zannikou, Markella
Duffy, Joseph T
Procissi, Daniele
Najem, Hinda
Levine, Rebecca N
Thakur, Aditi
Hambardzumyan, Dolores
Lee-Chang, Catalina
Leoni, Lara
Horbinski, Craig M
Simberg, Dmitri
Zhang, Bin https://orcid.org/0000-0002-6631-7647
Heimberger, Amy B https://orcid.org/0000-0002-9970-8695
Miska, Jason https://orcid.org/0000-0001-9608-2810
Balyasnikova, Irina V https://orcid.org/0000-0002-4664-9441
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04903795 at ClinicalTrials.govnct04903795 at ClinicalTrials.govDocuments that mention this clinical trial
Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors
https://doi.org/10.1136/jitc-2024-010500
For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
https://doi.org/10.1136/jitc-2021-003679
Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models
https://doi.org/10.1136/jitc-2025-011714
nct05168423 at ClinicalTrials.govDocuments that mention this clinical trial
Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors
https://doi.org/10.1136/jitc-2024-010500
For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
https://doi.org/10.1136/jitc-2021-003679
Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models
https://doi.org/10.1136/jitc-2025-011714
nct05660369 at ClinicalTrials.govDocuments that mention this clinical trial
Highlights in IO: next-generation CAR-T therapy for glioblastoma
https://doi.org/10.1136/jitc-2025-014670
Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models
https://doi.org/10.1136/jitc-2025-011714
Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions
https://doi.org/10.1136/jitc-2025-012308
Documents that mention this clinical trial
Highlights in IO: next-generation CAR-T therapy for glioblastoma
https://doi.org/10.1136/jitc-2025-014670
Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models
https://doi.org/10.1136/jitc-2025-011714
Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions
https://doi.org/10.1136/jitc-2025-012308
-
Funding
Funding for this research was provided by:
NIH (1S10-OD03221-01A1)
National Institute of Neurological Disorders and Stroke (NS101150)
National Institute of Neurological Disorders and Stroke (NS106379)
National Institute of Neurological Disorders and Stroke (NS122395)
National Cancer Institute (CA257958)
National Cancer Institute (P30-CA060553)
- License Information
